667 related articles for article (PubMed ID: 20649764)
1. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
Lomonte C; Martino R; Selvaggiolo M; Bona RM; Cazzato F; Milano R; Chiarulli G; Basile C
J Nephrol; 2003; 16(5):716-20. PubMed ID: 14733419
[TBL] [Abstract][Full Text] [Related]
4. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
6. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
7. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
8. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
9. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
10. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
[TBL] [Abstract][Full Text] [Related]
11. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
12. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
[TBL] [Abstract][Full Text] [Related]
14. [A clinical study on active vitamin D pulse therapy in hemodialysis patients with secondary hyperparathyroidism].
Ehara H; Nezasa S; Hagiwara N; Yamada T; Yasuda M; Nishino Y; Nishida Y; Takahashi Y; Ishihara S; Deguchi T
Hinyokika Kiyo; 2000 Mar; 46(3):165-8. PubMed ID: 10806572
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
16. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
17. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
18. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
19. Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism.
Beyer TD; Solorzano CC; Prinz RA; Babu A; Nilubol N; Patel S
Surgery; 2007 Jun; 141(6):777-83. PubMed ID: 17560254
[TBL] [Abstract][Full Text] [Related]
20. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
